{
  "schema_version": "5.0",
  "artifact_kind": "company_profile",
  "language": "zh-CN",
  "generated_on": "2026-11-03",
  "research_as_of": "2026-11-03",
  "input_context": {
    "name_zh": "信达生物",
    "name_en": "Innovent",
    "industry_level1": "医药健康",
    "industry_level2": "",
    "official_website": "www.innoventbio.com",
    "company_type": "品牌方",
    "logo_url": "https://img.logo.dev/www.innoventbio.com?token=pk_C1w9wXUfQkaYSJRJ-OQSCQ&size=256&format=webp&fallback=404"
  },
  "entity": {
    "name_zh": "信达生物",
    "scope": "Innovent Biologics, Inc.（信达生物制药）及其合并报表范围内子公司",
    "source_ids": [
      "S01"
    ]
  },
  "basic_info": [
    {
      "key": "legal_name",
      "label": "法定主体或所属主体",
      "value": "Innovent Biologics, Inc.（信达生物制药）",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "founded",
      "label": "成立时间",
      "value": "2011-04-28",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "headquarters",
      "label": "总部",
      "value": "中国江苏苏州",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "listing",
      "label": "上市情况",
      "value": "香港联合交易所主板，01801；2018-10-31上市",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "employees",
      "label": "员工人数",
      "value": 8754,
      "unit": "人",
      "as_of": "2026-06-30",
      "scope": "公司披露合并员工口径",
      "source_ids": [
        "S02"
      ],
      "display": "8,754人"
    },
    {
      "key": "revenue",
      "label": "营业收入",
      "value": 13041523000,
      "unit": "人民币元",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "合并报表总收入",
      "source_ids": [
        "S01"
      ],
      "display": "130.42亿元人民币"
    },
    {
      "key": "current_year_revenue",
      "label": "今年营业收入",
      "value": 8617801000,
      "unit": "人民币元",
      "period": {
        "start": "2026-01-01",
        "end": "2026-06-30",
        "basis": "calendar_year"
      },
      "scope": "合并报表累计收入；未经审计",
      "statement_date": "2026-09-29",
      "source_ids": [
        "S02"
      ],
      "display": "86.18亿元人民币"
    },
    {
      "key": "international_revenue",
      "label": "国际业务收入",
      "value": 972043000,
      "unit": "人民币元",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "中国以外客户经营所在地收入；含药品、许可、研发",
      "source_ids": [
        "S01"
      ],
      "display": "9.72亿元人民币"
    },
    {
      "key": "international_revenue_share",
      "label": "国际收入占比",
      "value": 7.45,
      "unit": "%",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "上述境外收入÷同年合并总收入，计算值",
      "source_ids": [
        "S01"
      ],
      "display": "7.45%"
    },
    {
      "key": "sales_coverage",
      "label": "销售覆盖国家及地区",
      "value": [
        "印度尼西亚",
        "美国"
      ],
      "scope": "部分已核实业务市场：印尼为药品商业化，美国为许可及研发客户收入；非欧美药品已销售认定",
      "source_ids": [
        "S01",
        "S10",
        "S11"
      ],
      "display": "印度尼西亚、美国"
    }
  ],
  "overview": {
    "paragraphs": [
      {
        "text": "信达生物采用开曼注册、香港上市的Innovent Biologics, Inc.及其合并子公司口径，中国总部位于苏州，苏州运营公司是集团成员。本报告覆盖已上市药品、授权合作和研发服务，既包括自主开发，也包括共同开发、引进销售及商业推广，不将合作药企的其他产品或人员并入集团。",
        "source_ids": [
          "S01",
          "S02",
          "S04"
        ]
      }
    ]
  },
  "business": {
    "paragraphs": [
      {
        "text": "商业组合围绕肿瘤和综合生物医药两条业务线展开。最新中期材料列出20款商业化药品，覆盖单抗、小分子靶向药、CAR-T细胞治疗、代谢及眼科药物。产品中心的中文名称与最新商业化清单逐项核对；唯择、维复泰等为合作引入的中国商业化项目，不能由经营权推断全部知识产权归信达。",
        "source_ids": [
          "S02",
          "S04",
          "S05"
        ]
      },
      {
        "text": "国际创新主要通过许可、共同开发及未来共同商业化推进，分子开发阶段与合同收入分开判断。IBI363、IBI343及多项ADC、多特异抗体仍在临床或注册开发中，不按欧美现售药品处理。集团已经确认的研发服务是向合作方交付研发成果的独立业务，而非自有药品销售的售后支持。",
        "source_ids": [
          "S02",
          "S03",
          "S04",
          "S06"
        ]
      }
    ],
    "brands": [
      {
        "name": "信达生物（Innovent）",
        "description": "企业品牌组织下列商业化药品组合；各药品商品名及合作权益分别保留，产品列示不代表集团拥有全部品牌全球权利。",
        "source_ids": [
          "S01",
          "S04",
          "S05"
        ],
        "website": "https://www.innoventbio.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "生物制药"
          }
        ],
        "products": [
          {
            "category": "抗肿瘤抗体药",
            "series": [],
            "representative_products": [
              {
                "name": "达伯舒（信迪利单抗）",
                "website": null
              },
              {
                "name": "达攸同（贝伐珠单抗）",
                "website": null
              },
              {
                "name": "达伯华（利妥昔单抗）",
                "website": null
              },
              {
                "name": "希冉择（雷莫西尤单抗）",
                "website": null
              },
              {
                "name": "达伯欣（伊匹木单抗N01）",
                "website": null
              }
            ],
            "description": "包括信迪利单抗创新药，贝伐珠单抗和利妥昔单抗生物类似药，以及合作引进的雷莫西尤单抗。伊匹木单抗N01为另一种肿瘤免疫药，非信迪利单抗型号。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "小分子抗肿瘤药",
            "series": [],
            "representative_products": [
              {
                "name": "达伯坦（佩米替尼）",
                "website": null
              },
              {
                "name": "耐立克（奥雷巴替尼）",
                "website": null
              },
              {
                "name": "睿妥（塞普替尼）",
                "website": null
              },
              {
                "name": "达伯特（氟泽雷塞）",
                "website": null
              },
              {
                "name": "捷帕力（匹妥布替尼）",
                "website": null
              },
              {
                "name": "达伯乐（他雷替尼）",
                "website": null
              },
              {
                "name": "奥壹新（利厄替尼）",
                "website": null
              },
              {
                "name": "唯择（阿贝西利）",
                "website": null
              },
              {
                "name": "维复泰（奎扎替尼）",
                "website": null
              }
            ],
            "description": "经营多种激酶靶向药，分子、开发方和区域权益各异。阿贝西利和奎扎替尼来自2026年新增合作商业化，不按集团自研药表述。",
            "source_ids": [
              "S01",
              "S02",
              "S04",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "CAR-T细胞治疗产品",
            "series": [],
            "representative_products": [
              {
                "name": "福可苏（伊基奥仑赛）",
                "website": null
              }
            ],
            "description": "福可苏为伊基奥仑赛注射液，属于与常规抗体药不同的细胞治疗商品，在合作模式下商业化。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "自身免疫疾病抗体药",
            "series": [],
            "representative_products": [
              {
                "name": "苏立信（阿达木单抗）",
                "website": null
              },
              {
                "name": "信美悦（匹康奇拜单抗）",
                "website": null
              }
            ],
            "description": "包括阿达木单抗生物类似药及自主研发的IL-23p19抗体匹康奇拜单抗，分别保留商品名称。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "降脂抗体药",
            "series": [],
            "representative_products": [
              {
                "name": "信必乐（托莱西单抗）",
                "website": null
              }
            ],
            "description": "信必乐为自主研发的PCSK9抗体托莱西单抗，用于血脂管理。",
            "source_ids": [
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "代谢多肽药",
            "series": [],
            "representative_products": [
              {
                "name": "信尔美（玛仕度肽）",
                "website": null
              }
            ],
            "description": "信尔美为玛仕度肽，属于GCG/GLP-1双受体激动剂，面向体重及代谢疾病管理。",
            "source_ids": [
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          },
          {
            "category": "眼科抗体药",
            "series": [],
            "representative_products": [
              {
                "name": "信必敏（替妥尤单抗N01）",
                "website": null
              }
            ],
            "description": "信必敏为替妥尤单抗N01注射液，是已上市的甲状腺眼病用药，与研发中的其他眼科资产分开。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.innoventbio.com/product/products"
          }
        ],
        "services": [
          {
            "name": "药物及技术许可",
            "description": "面向制药合作方许可分子开发或商业化权益，合同可包含首付款、分阶段里程碑、未来销售提成及共同开发安排。适用地域依项目约定，潜在总金额不当作收入。",
            "source_ids": [
              "S02",
              "S04",
              "S06"
            ],
            "website": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092900476.pdf"
          },
          {
            "name": "合作研发服务",
            "description": "运用发现、临床转化和早期临床能力为合作项目交付研发工作，按履约确认服务费。Pfizer项目包括推进至一期的研发职责，礼来项目推进至概念验证。",
            "source_ids": [
              "S02",
              "S04",
              "S06"
            ],
            "website": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092900476.pdf"
          }
        ]
      }
    ],
    "services": []
  },
  "global_presence": {
    "paragraphs": [
      {
        "text": "中国承担主要研发、生产及药品商业经营，集团美国子公司Fortvita在加州帕洛阿尔托有实际办公地点。国际业务通过武田、礼来、Pfizer、Roche等合作网络推进，合同地域涵盖欧美等区域，但临床试验所在地或未来商业化权利不等于现有药品销售市场。",
        "source_ids": [
          "S01",
          "S02",
          "S06",
          "S09"
        ]
      },
      {
        "text": "逐国可核实印尼已有贝伐珠单抗商业化，美国有按客户所在地确认的技术及研发交易收入；欧洲已有地域收入，但本次未取得足以拆分全部国家的材料。印度信迪利单抗已有许可合作线索，巴西、阿根廷、墨西哥在演示中明确为计划，均未因合作或计划直接计入已销售国家表。",
        "source_ids": [
          "S01",
          "S10",
          "S11"
        ]
      }
    ],
    "market_regions": [
      {
        "region": "亚洲",
        "countries": [
          "印度尼西亚"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01",
          "S10",
          "S11"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01",
          "S10",
          "S11"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      }
    ],
    "operating_regions": [
      {
        "region": "亚洲",
        "countries": [
          "中国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01",
          "S06",
          "S09"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01",
          "S06",
          "S09"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      }
    ]
  },
  "developments": {
    "window": {
      "start": "2025-11-03",
      "end": "2026-11-03",
      "max_items": 5
    },
    "items": [
      {
        "id": "D01",
        "title": "与Pfizer达成12项肿瘤项目全球合作",
        "importance": "major",
        "display_date": "2026-05-29",
        "summary": "签署覆盖12项早期肿瘤资产及发现项目的许可合作，部分项目约定未来欧美共同商业化。随后中期业绩公告称已收到6.5亿美元首付款。",
        "status": "announced",
        "source_ids": [
          "S04",
          "S06"
        ]
      },
      {
        "id": "D02",
        "title": "与礼来肿瘤及免疫合作协议生效",
        "importance": "major",
        "display_date": "2026-03-24",
        "summary": "FTC提前放行后，合作协议生效。信达负责中国概念验证阶段开发，礼来取得大中华区以外约定独家开发和商业化权。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S02",
          "S04",
          "S07"
        ]
      },
      {
        "id": "D03",
        "title": "与武田的许可合作及股权发行完成交割",
        "importance": "major",
        "display_date": "2025-12-05",
        "summary": "公告许可合作交割条件已满足，同时披露12月4日完成股份发行，涉及IBI363、IBI343及早期项目合作。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S04",
          "S08"
        ]
      }
    ]
  },
  "sources": [
    {
      "id": "S01",
      "title": "Innovent Biologics 2025 Annual Report",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2026-04-28"
    },
    {
      "id": "S02",
      "title": "Innovent Biologics 2026 Interim Report",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092900476.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2026-09-29"
    },
    {
      "id": "S03",
      "title": "2026年第三季度产品收入更新",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1029/2026102900053.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2026-10-29"
    },
    {
      "id": "S04",
      "title": "信达2026上半年业绩公告",
      "url": "https://investor.innoventbio.com/media/1355/hkex-eps_20260825_12298144_0.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-03",
      "published_at": "2026-08-25"
    },
    {
      "id": "S05",
      "title": "信达生物产品中心",
      "url": "https://www.innoventbio.com/product/products",
      "type": "official",
      "accessed_on": "2026-11-03"
    },
    {
      "id": "S06",
      "title": "信达与Pfizer全球战略许可合作",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052900029.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2026-05-29"
    },
    {
      "id": "S07",
      "title": "礼来合作协议生效公告",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0325/2026032500087.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2026-03-25"
    },
    {
      "id": "S08",
      "title": "与武田战略合作完成交割",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1205/2025120500041.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-03",
      "published_at": "2025-12-05"
    },
    {
      "id": "S09",
      "title": "Fortvita Biologics联系方式",
      "url": "https://www.fortvitabio.com/contact-us/",
      "type": "official",
      "accessed_on": "2026-11-03"
    },
    {
      "id": "S10",
      "title": "信达2023 ESG报告",
      "url": "https://img.innoventbio.com/2023ESG%E8%8B%B1%E6%96%87EN.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-03"
    },
    {
      "id": "S11",
      "title": "信达2025中期业绩演示",
      "url": "https://investor.innoventbio.com/media/1325/innovent-biologics_2025-semi-annual-results_website.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-03"
    }
  ],
  "report_template": "core-v4"
}